Recently, EZH2 inhibitors 16 and CPI-1205 (with an undisclosed structure) have entered clinical trials against EZH2 mutated non-Hodgkin lymphomas, while the results have not been disclosed. The gene discussed is EZH2; the disease is non-Hodgkin lymphoma.